Stock ROSE DOCMORRIS AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials DocMorris AG Berne S.E.

Equities

ROSE

CH0042615283

Drug Retailers

Real-time Estimate Cboe Europe
Other stock markets
 15:49:20 16/07/2024 BST 		5-day change 1st Jan Change
47.2 CHF 0.00% Intraday chart for DocMorris AG 0.00% 0.00%
07-12 DOCMORRIS : Hauck & Aufhauser reaffirms its Buy rating ZD
07-12 DOCMORRIS : Deutsche Bank reiterates its Buy rating ZD

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 928.7 2,708 2,412 320.6 867.3 609.3 - -
Enterprise Value (EV) 1 1,036 2,978 2,714 723.2 1,144 857.7 894.8 905.2
P/E ratio -17.7 x -18.9 x -10.1 x -1.61 x 10.5 x -6.67 x -21.8 x 25 x
Yield - - - - - - - -
Capitalization / Revenue 0.69 x 1.83 x 1.4 x 0.2 x 0.9 x 0.53 x 0.4 x 0.31 x
EV / Revenue 0.76 x 2.02 x 1.57 x 0.45 x 1.18 x 0.74 x 0.59 x 0.46 x
EV / EBITDA -75.1 x -38 x -19 x -9.31 x -29.8 x -35.2 x 28.2 x 12.4 x
EV / FCF -4.59 x -23.4 x -14 x -3.87 x -9.94 x -10.8 x -15.7 x -407 x
FCF Yield -21.8% -4.27% -7.15% -25.9% -10.1% -9.24% -6.35% -0.25%
Price to Book 1.67 x 5.09 x 5.44 x 0.84 x 2.01 x 1.49 x 1.58 x 1.48 x
Nbr of stocks (in thousands) 8,680 9,568 10,240 12,543 11,760 12,882 - -
Reference price 2 107.0 283.0 235.5 25.56 73.75 47.30 47.30 47.30
Announcement Date 19/03/20 18/03/21 24/03/22 24/03/23 20/03/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,356 1,477 1,726 1,608 966.9 1,152 1,517 1,960
EBITDA 1 -13.8 -78.4 -142.6 -77.7 -38.4 -24.36 31.7 73.11
EBIT 1 -45.7 -117.6 -193.8 -140.3 -83.2 -67.09 -15.79 41.33
Operating Margin -3.37% -7.96% -11.23% -8.72% -8.6% -5.83% -1.04% 2.11%
Earnings before Tax (EBT) 1 -50.1 -133.2 -226.7 -169.9 -118.7 -89.43 -38.5 30.68
Net income 1 -52.4 -135.6 -225.7 -171.1 82.2 -86.95 -32.9 23.56
Net margin -3.87% -9.18% -13.07% -10.64% 8.5% -7.55% -2.17% 1.2%
EPS 2 -6.040 -14.95 -23.40 -15.88 7.050 -7.089 -2.167 1.895
Free Cash Flow 1 -225.8 -127.3 -194.1 -187.1 -115.1 -79.22 -56.86 -2.225
FCF margin -16.65% -8.62% -11.24% -11.63% -11.91% -6.88% -3.75% -0.11%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 19/03/20 18/03/21 24/03/22 24/03/23 20/03/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 S2
Net sales 1 687.1 698 778.9 839.8 443.4 443.4 886.7 418.9 405.1 824 784.2 402.8 235.5 463 503.9 265 283 546 648.5
EBITDA -11.34 -24.45 -53.95 -49.71 - - -92.89 - - -43.08 -34.62 - - -28.1 - - - -39 5
EBIT - - - -73.11 - - -120.7 - - -69.45 -70.85 - - -48.8 - - - -61 -17
Operating Margin - - - -8.71% - - -13.61% - - -8.43% -9.03% - - -10.54% - - - -11.17% -2.62%
Earnings before Tax (EBT) - - - - - - - - - - -83.04 - - - - - - -61 -26
Net income - - - - - - -148.7 - - -86.09 - - - - - - - -61 -26
Net margin - - - - - - -16.77% - - -10.45% - - - - - - - -11.17% -4.01%
EPS - - - -8.030 - - - - - -8.290 -7.590 - - - - - - -5.170 -2.200
Dividend per Share - - - - - - - - - - - - - - - - - - -
Announcement Date 19/03/20 19/08/20 18/03/21 18/08/21 24/12/21 24/03/22 24/03/22 18/05/22 18/08/22 18/08/22 24/03/23 17/05/23 17/08/23 17/08/23 20/03/24 - - - -
1CHF in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 107 270 303 403 277 248 285 296
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) -7.768 x -3.444 x -2.123 x -5.181 x -7.208 x -10.2 x 9.004 x 4.047 x
Free Cash Flow 1 -226 -127 -194 -187 -115 -79.2 -56.9 -2.23
ROE (net income / shareholders' equity) -12.3% -28.9% -44.4% -39% -29.2% -23.3% -12% 0.38%
ROA (Net income/ Total Assets) -6.09% -11.9% -17.7% -13.8% -11.6% -8.02% -2.38% 2.16%
Assets 1 859.8 1,135 1,274 1,242 -708 1,084 1,383 1,090
Book Value Per Share 2 63.90 55.60 43.30 30.40 36.60 31.80 30.00 31.90
Cash Flow per Share 2 -9.530 -7.440 -13.00 -9.030 -7.490 -2.280 -1.150 3.270
Capex 1 10.4 59.8 63.5 59.3 27.7 32.2 33.4 36.5
Capex / Sales 0.77% 4.05% 3.68% 3.69% 2.87% 2.8% 2.2% 1.86%
Announcement Date 19/03/20 18/03/21 24/03/22 24/03/23 20/03/24 - - -
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for DocMorris AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
47.3 CHF
Average target price
91.83 CHF
Spread / Average Target
+94.15%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

1st Jan change Capi.
WALGREENS BOOTS ALLIANCE, INC. Stock Walgreens Boots Alliance, Inc.
-54.56% 10.1B
JD HEALTH INTERNATIONAL INC. Stock JD Health International Inc.
-46.55% 8.81B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED Stock Alibaba Health Information Technology Limited
-25.71% 6.65B
MATSUKIYOCOCOKARA & CO. Stock MatsukiyoCocokara & Co.
-4.16% 6.45B
CORPORATIVO FRAGUA, S.A.B. DE C.V. Stock Corporativo Fragua, S.A.B. de C.V.
+97.00% 5.35B
NAHDI MEDICAL COMPANY Stock Nahdi Medical Company
-2.92% 4.63B
CLICKS GROUP LIMITED Stock Clicks Group Limited
+8.08% 4.6B
YIFENG PHARMACY CHAIN CO., LTD. Stock Yifeng Pharmacy Chain Co., Ltd.
-33.29% 3.79B
REDCARE PHARMACY NV Stock Redcare Pharmacy NV
+7.98% 3.13B
Other Drug Retailers
  1. Stock Market
  2. Equities
  3. ROSE Stock
  4. ROSE Stock
  5. Financials DocMorris AG